Skip to main content
. Author manuscript; available in PMC: 2012 Jul 5.
Published in final edited form as: Eur J Clin Pharmacol. 2007 Dec 19;64(2):207–216. doi: 10.1007/s00228-007-0427-9

Fig. 7.

Fig. 7

Predicted natural UPDRS progression from study entry with linear model (dashed) or Gompertz model (solid). Symptomatic and protective effects of levodopa 300 mg/day alone (dash dot) and with deprenyl 10 mg/day, (dash dot dot) are shown from 2 years